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Abstract 
Background: Anti-malarial compounds have not yet been identified that target the first obligatory step of infection 
in humans: the migration of Plasmodium sporozoites in the host dermis. This movement is essential to find and invade 
a blood vessel in order to be passively transported to the liver. Here, an imaging screening pipeline was established to 
screen for compounds capable of inhibiting extracellular sporozoites.
Methods: Sporozoites expressing the green fluorescent protein were isolated from infected Anopheles mosquitoes, 
incubated with compounds from two libraries (MMV Malaria Box and a FDA-approved library) and imaged. Effects on 
in vitro motility or morphology were scored. In vivo efficacy of a candidate drug was investigated by treating mice 
ears with a gel prior to infectious mosquito bites. Motility was analysed by in vivo imaging and the progress of infec-
tion was monitored by daily blood smears.
Results: Several compounds had a pronounced effect on in vitro sporozoite gliding or morphology. Notably, monen-
sin sodium potently affected sporozoite movement while gramicidin S resulted in rounding up of sporozoites. How-
ever, pre-treatment of mice with a topical gel containing gramicidin did not reduce sporozoite motility and infection.
Conclusions: This approach shows that it is possible to screen libraries for inhibitors of sporozoite motility and 
highlighted the paucity of compounds in currently available libraries that inhibit this initial step of a malaria infec-
tion. Screening of diverse libraries is suggested to identify more compounds that could serve as leads in developing 
‘skin-based’ malaria prophylactics. Further, strategies need to be developed that will allow compounds to effectively 
penetrate the dermis and thereby prevent exit of sporozoites from the skin.
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Background
The increasing emergence of resistance to front-line 
anti-malarial drug artemisinin emphasizes the need for 
identification and development of novel drug candidates 
[1–3]. To reduce the occurrence of drug resistance, the 
malaria parasite Plasmodium should be blocked at mul-
tiple stages of the life cycle [3–7]. In line with this, many 
studies have attempted to screen for compounds that are 
potent inhibitors of liver stage development, blood stage 
growth, gametocyte integrity, or transmission into the 
mosquito (or a combined potency of all of these) [8–27]. 
While often overlooked, the sporozoite stage of the life 
cycle presents a possible opportunity for prophylaxis 
[28–32]. Sporozoites form in oocysts within the mosquito 
vector and need their motility first to be released into the 
haemocoel of the insect [33], where they passively drift 
before actively invading salivary glands [34–36]. Dur-
ing mosquito probing for a blood meal, sporozoites flow 
out with the saliva and are deposited in the skin of the 
mammalian host [30, 37–40]. Sporozoites, powered by 
an actomyosin system, move rapidly through the dermis 
using a form of locomotion referred to as gliding motility 
[30, 41, 42]. Sporozoites then associate with blood vessels 
and enter the blood stream whereby they passively drift 
before invading hepatocytes [29, 30, 43–45].
Sporozoites are a viable target for malaria prophylaxis 
for several reasons. Firstly, sporozoite deposition into the 
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skin presents a population bottleneck. Approximately 
1–100 sporozoites are introduced into the skin during 
probing and thus only a small number of parasites need 
to be inhibited and/or cleared by the immune system [30, 
38, 46]. Secondly, the skin step is the longest extracellu-
lar stage of the life cycle in the human host (estimated 
to be more than 10 min) [37] and thus, due to this long 
exposure outside of a host cell, might be possibly more 
vulnerable to appropriate drugs or immune responses 
than merozoites. Stalling sporozoites in the skin could 
allow for sufficient time for the phagocytic cells of the 
immune system to clear them [47]. Indeed, inhibiting 
sporozoite migration can be achieved by antibodies tar-
geting the circumsporozoite protein CSP [42, 48, 49]. 
Thirdly, sporozoites might possibly be targeted by com-
pounds directly applied to the skin, perhaps administered 
in the form of a daily body lotion or soap, thus avoiding 
the difficult pharmacological parameters of toxicity and 
bioavailability that many orally administered candidates 
encounter. Lastly, inhibitors of sporozoite motility could 
display broader inhibition of other stages and thus might 
also inhibit the active invasion of merozoites (needed for 
red blood cell invasion) and motility of midgut penetrat-
ing ookinetes.
To date, there have been no compound library screens 
performed on whole sporozoites to identify direct inhibi-
tors of extracellular sporozoite motility. Here, the results 
of screens using two available drug libraries against 
motile sporozoites are presented. Using this approach, 
three compounds from the MMV Malaria Box (out of six 
initial hits) and antimicrobial ionophores monensin and 
gramicidin were identified as possible lead candidates 
for the potential use in malaria skin phase prophylaxis 
should an appropriate delivery method become available. 
These data also show that only a few compounds show 
inhibitory effects, suggesting that compounds identified 
from screens against a multiplying parasite might not 
be suited for repurposing to inhibit motile extracellular 
stages.
Methods
Compound libraries
Two compound libraries were tested for effects on iso-
lated sporozoites: the MMV Malaria Box and a short-
listed version of a library containing FDA-approved 
drugs [8]. The Malaria Box is a library of approximately 
400 compounds that were initially identified as hits of 
Plasmodium falciparum asexual blood stage develop-
ment [10] and later screened for effects at other life 
cycle stages as well as different pathogens [9]. The FDA-
approved drug library was made up of 1037 drugs that 
have received approval for human or animal use in the 
treatment of a spectrum of diseases. This library was 
chosen as any hits identified from this screen would 
possess desired drug-like properties, thereby accelerat-
ing the discovery to application process and thus save 
time, money and licensing complications. A screen of 
the entire library against Plasmodium berghei liver stage 
invasion and/or development has already been per-
formed [8]. Ninety-seven relevant hits from this screen 
(which could be targeting motility, invasion and/or intra-
cellular development) were acquired as a potential drug 
short-list and assessed for direct effects on sporozoites.
In vitro screening assay for sporozoite motility inhibition
Rodents infected with P. berghei (NK65 strain express-
ing GFP under the CSP promoter) were anesthetized, 
and starved mosquitoes allowed to feed. Salivary glands 
of infected mosquitoes (days 17–24 post-infection) were 
isolated by dissection, parasites placed into RPMI-1640 
P/S buffer (supplemented with 50,000 units  l−1 penicil-
lin and 50  mg  l−1 streptomycin), released by mechani-
cal crushing and briefly centrifuged. Sporozoites were 
resuspended in activation medium (RPMI-1640 P/S 
supplemented with 6% bovine serum albumin) and ali-
quoted into a 384-well plate to a final amount of approxi-
mately 2000 sporozoites per well. An equal volume of 
inhibitor (in RPMI-1640 P/S) was added promptly to the 
sporozoites to give a final concentration of either 1  µM 
or 10  µM and mixed by gentle pipetting. Some com-
pounds of the Malaria Box were excluded due to high 
background fluorescence and thus affected the visualisa-
tion of sporozoites: MMV006309 and MMV009127. The 
sporozoite-inhibitor mixture was centrifuged for 3 min at 
1000  rpm to maximise sporozoite numbers adhering to 
the glass, incubated for 30 min and each well imaged at 
1  Hz for 30  s. To identify a maximum number of com-
pounds, and due to the large number of compounds 
screened, the limitations of the number of sporozoites 
that one needs for screening and the nature of the assay 
itself (live imaging on parasites that only move for a short 
time), all initial hit identification in the pilot screen was 
done with a single assay per compound. All compounds 
from both libraries were first assessed with automated 
tracking software ToAST [50] and subsequently visually 
for changes in motility (by maximum intensity z-pro-
jections) and sporozoite morphology. Compounds that 
showed potent inhibition in the pilot screen were further 
assessed for inhibition reproducibility with at least two 
additional biological replicates. Sporozoites were classed 
as moving if they moved more than 1 parasite length dur-
ing the 30-s acquisition. The percentage residual motile 
population was then calculated and compared to unin-
hibited controls (buffer solution containing an equiva-
lent amount of DMSO). Compounds displaying > 75% 
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inhibition at these conditions were considered for in vivo 
characterization.
In vivo validation of  Tyrosur® gel
To fully characterize the in vivo efficacy of one of the hits, 
a rodent model of infection was employed. All animal 
experiments were performed according to FELASA B and 
GV-SOLAS standard guidelines. Animal experiments 
were approved by the German authorities (Regierung-
spräsidium Karlsruhe, Germany). Approximately 100 mg 
of  Tyrosur® gel formulation (Engelhard Arzneimittel) 
was applied to the ear 4  h before the bite experiment. 
Mice were then anesthetized with a ketamine/xylazine 
mixture (87.5 mg kg  ketamine−1, 12.5 mg kg−1 xylazine, 
administered intraperitoneally) and infected mosqui-
toes allowed to bite on a single mouse ear for 10–20 min. 
For in vivo imaging on the ears of living mice, mice were 
anesthetized as above and the hair removed by treatment 
with hair removal cream (Veet) for 5  min 24  h prior to 
mosquito bite. The next day, mice were again anesthe-
tized and infected mosquitoes allowed to bite the treated 
ear. Upon observation of a mosquito bite, the anesthe-
tized mouse was immediately moved onto a heated 
chamber wide field microscope (Zeiss Axiovert TM200), 
the bite site identified and sporozoites imaged at 1 frame 
every 3 s for 5 min as described previously [51]. To moni-
tor infection progression post-mosquito bite, mice were 
given standard drinking water and monitored daily from 
day 3 after biting by Giemsa staining to measure the pre-
patent period and subsequent blood stage growth and 
compared to control mice, which were treated by a con-
trol cream (Vaseline). Mann–Whitney statistical tests 
were conducted for non-parametric datasets.
Results
MMV Malaria Box screen identifies potent inhibitors 
of sporozoite motility
The Malaria Box has been used as a screening toolbox 
for the various stages of the Plasmodium life cycle [9] 
(Fig.  1a). Here, it was investigated whether compounds 
from this library were capable of directly inhibiting 
in vitro sporozoite motility. To this end, sporozoites were 
isolated from freshly dissected mosquito salivary glands 
and incubated with library compounds for 30  min. The 
effects of these compounds were then assessed by direct 
visualization (Fig. 1b). This identified six compounds that 
reproducibly displayed > 50% inhibition of sporozoite 
motility (Fig.  1c, Additional file  1: Table  S1, Additional 
file 2: Figure S1). As a positive inhibitor control, sporozo-
ites were treated with 1 µM cytochalasin D (Cyto D), an 
actin toxin previously shown to be a potent inhibitor for 
sporozoite movement [52]. Treatment with Cyto D com-
pletely abrogated sporozoite motility and resulted in more 
adherent sporozoites consistent with previous observa-
tions (Fig.  2a) [52, 53]. Interestingly, of the hits identi-
fied, there were two pairs that shared the same starting 
scaffold (MMV665953 and MMV665852; MMV665794 
and MMV007224). MMV665953 and MMV665852 are 
part of a family of four related compounds in the Malaria 
Box with the other two compounds (MMV000911 and 
MMV001318) not showing any noticeable activity against 
sporozoites in the pilot screen. In terms of potency, 
three compounds (MMV665953, MMV665852 and 
MMV007224) displayed approximately > 75% inhibition 
(Fig. 1a). However, due to reported toxic effects on hepat-
ocytes [9] and a lack of a currently available topical treat-
ment, these compounds were not further tested in vivo. 
A sub‑set of compounds from an FDA‑approved drug 
library are micromolar inhibitors of sporozoites
A previous study made use of an FDA-approved drug 
library to screen for liver stage drug candidates, resulting 
in the identification of decoquinate as a promising mul-
tistage anti-malarial [8]. In this study, sporozoites were 
incubated with the compounds and added to liver cells. 
As a read-out, the development of liver stage parasites 
was used. This could be affected by either inhibiting liver 
stage growth or by liver cell invasion or gliding motility 
of sporozoites. A pilot screen was performed on the 97 
drugs that were anticipated to have an effect on extracel-
lular sporozoite motility and possibly not on liver devel-
opment (Additional file  1: Table  S1). From these only a 
small set of compounds showed prominent inhibition at 
the screening concentration of 1  µM (> 75% inhibition 
compared to DMSO control, Fig.  2b, c). These included 
zinc pyrithione, niclosamide and ionophores monensin 
sodium and gramicidin. Interestingly, monensin sodium 
completely blocked sporozoite motility by affecting 
proper sporozoite adhesion to the glass surface while not 
affecting shape (Fig. 2b). Gramicidin S treatment resulted 
in a pronounced rounding up of sporozoites presumably 
through membrane destabilization (Fig.  2c). Curiously 
tyrothricin, a mixture of tyrocidines and gramicidins, 
had a lesser effect on sporozoite morphology than grami-
cidin alone. Nonetheless at 10 µM concentration a simi-
lar effect on sporozoites could be observed as for 1 µM 
gramicidin. Given this observation, and that an inex-
pensive topical gel formulation containing tyrothricin 
(and hence gramicidin) was available, the antibacterial 
 Tyrosur® gel was selected for further in vivo analysis.
Pre‑treatment with  Tyrosur® gel does not significantly 
affect sporozoite infection ability in mice
Tyrosur® gel is used to treat and prevent infections of the 
skin [54, 55]. In order to assess whether pre-treatment 
of mouse skin with  Tyrosur® gel was able to affect the 
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ability of sporozoites to infect new hosts, a mouse model 
was employed (Fig. 3a). Mice were treated with  Tyrosur® 
or control gels 4 h prior to exposure to infected mosqui-
toes that were allowed to probe and feed on the treated 
(or control) region. Mice were subsequently placed on a 
heated stage of a microscope and fluorescent sporozo-
ites filmed as they migrated in the skin (Fig.  3a). Image 
analysis revealed no difference between the two groups of 
mice in terms of sporozoite speed and migration pattern 
(Fig. 3b, c). Thus, pre-treatment of mice ears with a topi-
cal application of gel did not affect sporozoite motility in 
the host skin. Consistent with these observations, mice 
exposed to infected mosquito bites showed no signifi-
cant difference in prepatent period compared to controls, 
suggesting that this treatment also does not significantly 
affect sporozoite viability after skin exit and entry into 
the liver (Fig. 2d).
Discussion
The skin phase of Plasmodium is surprisingly often over-
looked in reviews describing drug discovery or vaccina-
tion strategies in the malaria field [28]. Not only is this 
unfortunate in terms of omission of an important part of 
the parasite biology, but it also misses the important con-
sideration of the skin being an additional area for infec-
tion prevention. The possibility of skin phase prophylaxis 
has been proposed in previous studies [29–32]. Indeed, 
antibodies to the major surface protein of sporozoites 
have been shown to affect sporozoite movement in the 
skin [42] and could therefore contribute to the effects 
of the RTS,S vaccine [56, 57]. Many groups have per-
formed screens assessing for antimalarial candidates act-
ing at various or combined stages of the parasite life cycle 
[8–27]. However, to date only one paper has specifically 
screened and analysed inhibitors of whole sporozoites 
Fig. 1 Overview of previous and current screening strategies. a Previously, researchers have screened for compounds active at multiple stages 
(indicated in red text) yet there are no studies directly attempting to stop skin phase sporozoites (green text). b Summary of the current screening 
approach. Plasmodium berghei sporozoites are isolated from freshly dissected Anopheles stephensi mosquitoes and incubated with compounds 
for 30 min. Sporozoites are imaged and the effects on motility and morphology noted. Scale bar: 10 μm. c The Malaria Box is a condensed hit 
library from a large set of blood stage positive hits. The motility screen identified 6 compounds that displayed noticeable inhibition of extracellular 
sporozoites
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that could in principle directly act on motile parasites in 
the skin itself, although it investigated sporozoite-liver 
cell interactions [32]. A second paper made use of a com-
putational screen for a particular complex of proteins 
and evaluated the hits on sporozoites yet did not screen 
libraries on whole sporozoites [58].
In this study, two compound libraries were screened 
to test for in  vitro sporozoite inhibition. The MMV 
Malaria Box contained three molecules that fulfilled the 
criteria of potent inhibition of motility (MMV665953, 
MMV665852, MMV007224). These were part of the list 
also identified in two separate liver stage screens (which 
identified 43 candidates) but it is important to note that 
the compounds identified in the current study were all 
previously identified as toxic for hepatocytes [9]. None-
theless, the shorter list of identified compounds might 
still serve as useful leads in stopping sporozoites that 
now require further optimization for delivery. Further, 
these hits also assist the understanding of the liver stage 
hits identified previously. These data strongly suggest 
that the other liver stage hits observed for Malaria Box 
compounds published previously [9] are probably acting 
either during invasion of the hepatocyte and/or during 
subsequent intracellular development, but not before. 
The small number of hits that were identified as sporo-
zoite inhibitors from the blood stage inhibiting Malaria 
Box library also suggest that the sporozoites show few 
overlapping targets with other stages. Indeed there is 
strong evidence for global downregulation of translation 
in sporozoites [59, 60] and thus fewer targets could be 
available.
MMV665953 and MMV665852 were potent mol-
ecules while structurally similar compounds of the 
N,N′-Diarylurea backbone family (MMV000911 and 
MMV001318) were not. The consistent feature of the 
two hits is the preservation of the meta/para halides 
and thus these functional groups should be considered 
in any subsequent derivative design. The current sug-
gested target for this group of compounds is possibly 
cGMP-dependent protein kinase (PKG) [9], a key regu-
lator of multiple cellular processes. Interestingly, PKG 
has been shown to be involved in phosphorylation of 
Fig. 2 Screening against freshly isolated salivary gland sporozoites. a 3 Malaria Box compounds (at 10 µM) displayed potent inhibition of sporozoite 
motility (> 75% inhibition). b Selected drugs from the FDA approved library also displayed potent inhibition at 1 µM, with monensin sodium 
treatment pronouncedly inhibiting proper sporozoite attachment and motility. In both a and b, Cytochalasin D was used as a positive inhibitor 
control. c Gramicidin (1 µM) was potent in causing sporozoites to round up, while tyrothricin needed to be at a tenfold higher concentration for a 
similar effect. Data represented as mean ± SD. Scale bars: 10 µm
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gliding machinery components and is important for 
both merozoite red blood cell invasion and ookinete 
motility [61–63]. It is thus reasonable that inhibition 
of this kinase would affect sporozoite motility as well, 
although inducible knockout of PKG did not appear to 
affect liver cell invasion of sporozoites suggesting addi-
tional targets of these compounds and/or compensa-
tion by other kinases after deletion [64].
Thrombospondin-related anonymous protein (TRAP) 
is a prominent parasite adhesin involved in parasite 
gliding and organ penetration [34, 65, 66]. The other 
potent hit from the MMV library, MMV007224, has 
been recently identified as a molecule that might immo-
bilize an aldolase–TRAP interaction thereby affect-
ing sporozoite motility [58]. While aldolase does not 
have a direct role in motility [67, 68], affecting TRAP 
dynamics on the parasite plasma membrane by stabiliz-
ing a non-specific interaction could have consequences 
for efficient motility. The aldolase–TRAP study also 
identified other compounds from the library that were 
not notably active in the assay used here, presumably 
because these displayed weaker activities compared to 
MMV007224. Taken together, this shortlist of MMV 
malaria box compounds are useful in understanding 
contributors to parasite motility and could be used as 
leads to generate selective agents that stop sporozoite 
motility prior to invading the liver.
In the second screen, 97 compounds were used from a 
study that screened for liver stage inhibitors [8]. In that 
study, sporozoites were added together with the com-
pounds to hepatocytes and the read out was liver stage 
growth. Thus, this assay setup could not distinguish 
between a compound affecting parasite motility, inva-
sion, viability or growth. Four potent molecules inhib-
ited sporozoite motility at 1 µM concentration. Of these 
four compounds the two most potent candidates (mon-
ensin and gramicidin) belonged to the ionophore class 
of compounds. This category of antibiotic is particularly 
attractive since it targets membranes and therefore has 
reduced likelihood of generation of resistant strains [69]. 
Monensin is a polyether antibiotic that, when inserting 
into membranes, results in sodium and potassium fluxes 
that negatively affects ion homeostasis within cells [70]. It 
has been employed in ruminant cattle, primarily for the 
treatment of coccidiosis. Monensin has been shown to be 
active against Plasmodium at different stages including 
asexual blood stages, gametocytes and oocyst formation 
[71, 72] although long incubation times were required. 
Interestingly, pretreatment of hepatocytes with monen-
sin had a potent effect on sporozoite and Toxoplasma 
tachyzoite invasion; while pre-treatment of sporozoites 
Fig. 3 Pre-treatment with a tyrothricin and gramicidin containing topical gel  (Tyrosur®) did not inhibit in vivo parasite progression. a Mice ear hair 
was removed 24 h before the experiment and mosquito bites 4 h post-topical treatment. Anesthetized mice were transferred to a heated chamber 
and the bite site imaged to reveals sporozoites (left image). Time lapse recording enabled analysis of migration as shown exemplary by a projection 
of the sporozoite path over 450 s (right). Scale bar: 10 μm. b In vivo imaging of sporozoites deposited in the skin by mosquito bites moved at similar 
speeds (Mann–Whitney test, red line indicates median speed); and, c with similar mean square displacement (MSD) when compared to controls. d 
Mice were monitored after mosquito bite to assess any ‘post-skin’ effects of Tyrosur treatment. Parasite emergence in the blood was similar between 
groups indicating no prominent effect of Tyrosur after skin exit. Data represented as mean ± SEM
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with 1 µM monensin before applying to the hepatocytes 
only resulted in a 70% reduction [70]. This suggested the 
primary potency was mediated through host cell medi-
ated effects. At the same concentration in the assays used 
in this study, there was a reduction in sporozoite motility. 
This difference is probably best explained by the differ-
ent environments of sporozoite motility. It is reasonable 
to suggest that effects in a simple 2D environment (our 
assay) has more striking effects on adhesion while the 
three-dimensional environment during cell traversal 
[70] could require more compound for the same effect. 
Indeed a similar effect between environments has been 
observed with mutated parasite lines, which were largely 
unable to move in 2D but showed no defect in 3D [73, 
74]. Surrogate systems that mimic the three dimensional 
nature of the skin are currently being developed that 
could be used to test any future potential drug candidates 
in a 3D environment prior to in vivo testing [75].
Tyrothricin is isolated from Bacillus brevis and con-
sists of a mixture of cyclic decapeptides, gramicidin S and 
tyrocidine A. Similar to monensin, gramicidin is a poly-
peptide that produces membrane pores and affects cation 
gradients [76]. Given the general targeting of membranes, 
it is not surprising that ionophores have been shown to 
be effective in inhibiting Plasmodium blood stage growth 
[71, 77–79]. It is interesting that tyrothricin, a mixture 
of ionophoric peptides, was not as potent in sporozo-
ite rounding as gramicidin. This suggests that the active 
ingredient against sporozoites is more specifically grami-
cidin (which is only a fraction of tyrothricin). Tyrocidine 
peptides appear to be the primarily potent molecules 
against blood stage parasites with an IC50 value in the 
low micromolar range [79]. The difference between 
potencies of tyrothricin and gramicidin against sporozo-
ites might provide a subtle hint that membrane suscepti-
bilities are different across the life cycle. Different effects 
between other ionophores were also noticed: monensin 
affected proper sporozoite adhesion while gramicidin 
led to rounding up of sporozoites. While the molecu-
lar details are currently not clear regarding the altered 
response, it is reasonable to speculate that differences in 
pore sizes formed by these agents could affect dynamics 
of both the plasma and organellar membranes [80–84].
Ionophores have been used effectively in both the topi-
cal and systemic treatment of gram-positive bacterial 
infections [85]. Given the micromolar in vitro inhibition 
of the tyrothricin mixture, with the presence of gramici-
din in its overall composition and the availability of a gel 
formulation for topical application, we decided to fur-
ther analyse  Tyrosur® gel for possible in  vivo effects on 
deposited sporozoites. However, treatment of mice ears 
with  Tyrosur® gel did not significantly affect sporozoite 
infection ability after mosquito bite. Given the lack of 
inhibition even with large amounts of gel applied, it does 
suggest that the drug is not able to sufficiently permeate 
the dermal layer where sporozoites are predominantly 
located after  the bite. Thus, reduced drug accessibility 
to the essential skin layer could be the major cause of 
treatment failure. Recent publications indicate good pro-
gress on developing and modelling dermal penetration 
of exogenous molecules [86–89] but there still remains a 
long way to go before this could be used effectively in the 
field. Since this is a critical point, future work should thus 
focus on applying enhanced delivery methods that might 
allow targeting of the parasite and prevention of infec-
tion. Further, orally administered drugs should not be 
excluded as it is also possible that, if able to permeate the 
dermal layer via the blood, one could achieve the same 
effect of sporozoite motility in the skin. Such dermal 
penetration has been suggested previously in the case of 
passive intravenous transfer of CSP antibodies [42]. Our 
platform could thus also be used to quantitatively evalu-
ate other antibodies against sporozoite proteins.
Conclusion
In this study, a screening pipeline has been established 
and utilised to directly assess the potential effects of dif-
ferent drug candidates on extracellular sporozoite motil-
ity. Through this approach, a small set of molecules have 
been identified, including three MMV Malaria Box com-
pounds and two ionophores, that have potent effects on 
sporozoites viability in  vitro. However, much further 
development is needed such that compounds can be 
effectively delivered to an intact dermis. Given the small 
numbers of hits on sporozoites, screening of larger librar-
ies is needed.
Additional files
Additional file 1: Table S1. Initial pilot screen of MMV Malaria Box and 
FDA approved compounds.
Additional file 2: Figure S1. Structures of inhibitors showing >50% 
inhibition.
Authors’ contributions
FF conceived the study. FF and RD designed experiments. RD, MR and MN 
conducted experiments and analysed the data. All authors contributed to 
data interpretation. RD and FF wrote the manuscript (with contributions from 
all authors). All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Janina Hellmann, Conny Bernecker, Marta-Lena Müller, 
Stephan Hegge, Kai Matuschewski and Michael Hannus for contributions to 
the initial work leading to this study. The authors also thank the Medicines for 
Malaria Venture (MMV) for sharing the Malaria Box library free of charge to the 
malaria research community.
Page 8 of 10Douglas et al. Malar J  (2018) 17:319 
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the 
article (and its additional files).
Consent for publication
All authors approved the manuscript for submission.
Ethics approval and consent to participate
All animal experiments were performed according to FELASA B and GV-SOLAS 
standard guidelines. Animal experiments were approved by the German 
authorities (Regierungspräsidium Karlsruhe, Germany).
Funding
Funding by the Federal Germany Ministry for Education and Research (BMBF-
NGFN 01GR0820) and the Human Frontier Science Program (HFSP—RGY 
0071/2011) is acknowledged. RD and MN received postdoctoral and Summer 
School fellowships from the CellNetworks cluster of excellence at Heidelberg 
University. We acknowledge financial support by Deutsche Forschungsge-
meinschaft within the funding programme Open Access Publishing, by 
the Baden-Württemberg Ministry of Science, Research and the Arts and by 
Ruprecht-Karls-Universität Heidelberg.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 2 July 2018   Accepted: 27 August 2018
References
 1. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: biology and disease. 
Cell. 2016;167:610–24.
 2. Tilley L, Straimer J, Gnadig NF, Ralph SA, Fidock DA. Artemisinin 
action and resistance in Plasmodium falciparum. Trends Parasitol. 
2016;32:682–96.
 3. Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmo-
dium falciparum parasite biology to the clinic. Nat Med. 2017;23:917–28.
 4. Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery—
approaches and progress towards new medicines. Nat Rev Microbiol. 
2013;11:849–62.
 5. Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Design-
ing the next generation of medicines for malaria control and eradication. 
Malar J. 2013;12:187.
 6. Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, 
Kaszubska W, Macintyre F, et al. New developments in anti-malarial target 
candidate and product profiles. Malar J. 2017;16:26.
 7. Katsuno K, Burrows JN, Duncan K, Hooft van Huijsduijnen R, Kaneko T, 
Kita K, et al. Hit and lead criteria in drug discovery for infectious diseases 
of the developing world. Nat Rev Drug Discov. 2015;14:751–8.
 8. da Cruz FP, Martin C, Buchholz K, Lafuente-Monasterio MJ, Rodri-
gues T, Sonnichsen B, et al. Drug screen targeted at Plasmodium liver 
stages identifies a potent multistage antimalarial drug. J Infect Dis. 
2012;205:1278–86.
 9. Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, et al. 
Open source drug discovery with the Malaria Box compound collection 
for neglected diseases and beyond. PLoS Pathog. 2016;12:e1005763.
 10. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TN, Willis 
P. The open access malaria box: a drug discovery catalyst for neglected 
diseases. PLoS ONE. 2013;8:e62906.
 11. Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, Fisher N, 
et al. Discovery of potent small-molecule inhibitors of multidrug-resistant 
Plasmodium falciparum using a novel miniaturized high-throughput 
luciferase-based assay. Antimicrob Agents Chemother. 2010;54:3597–604.
 12. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, et al. In 
silico activity profiling reveals the mechanism of action of antimalarials 
discovered in a high-throughput screen. Proc Natl Acad Sci USA. 
2008;105:9059–64.
 13. Plouffe DM, Wree M, Du AY, Meister S, Li F, Patra K, et al. High-throughput 
assay and discovery of small molecules that interrupt malaria transmis-
sion. Cell Host Microbe. 2016;19:114–26.
 14. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al. 
Thousands of chemical starting points for antimalarial lead identification. 
Nature. 2010;465:305–10.
 15. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, et al. 
Chemical genetics of Plasmodium falciparum. Nature. 2010;465:311–5.
 16. Ekland EH, Schneider J, Fidock DA. Identifying apicoplast-targeting 
antimalarials using high-throughput compatible approaches. FASEB J. 
2011;25:3583–93.
 17. Gego A, Silvie O, Franetich JF, Farhati K, Hannoun L, Luty AJ, et al. New 
approach for high-throughput screening of drug activity on Plasmodium 
liver stages. Antimicrob Agents Chemother. 2006;50:1586–9.
 18. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, et al. 
Imaging of Plasmodium liver stages to drive next-generation antimalarial 
drug discovery. Science. 2011;334:1372–7.
 19. Derbyshire ER, Prudencio M, Mota MM, Clardy J. Liver-stage malaria 
parasites vulnerable to diverse chemical scaffolds. Proc Natl Acad Sci USA. 
2012;109:8511–6.
 20. Avery VM, Bashyam S, Burrows JN, Duffy S, Papadatos G, Puthukkuti S, 
et al. Screening and hit evaluation of a chemical library against blood-
stage Plasmodium falciparum. Malar J. 2014;13:190.
 21. Vos MW, Stone WJ, Koolen KM, van Gemert GJ, van Schaijk B, Leroy D, 
et al. A semi-automated luminescence based standard membrane feed-
ing assay identifies novel small molecules that inhibit transmission of 
malaria parasites by mosquitoes. Sci Rep. 2015;5:18704.
 22. Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, et al. 
A novel multiple-stage antimalarial agent that inhibits protein synthesis. 
Nature. 2015;522:315–20.
 23. Lucantoni L, Silvestrini F, Signore M, Siciliano G, Eldering M, Dechering KJ, 
et al. A simple and predictive phenotypic high content imaging assay for 
Plasmodium falciparum mature gametocytes to identify malaria transmis-
sion blocking compounds. Sci Rep. 2015;5:16414.
 24. Hovlid ML, Winzeler EA. Phenotypic screens in antimalarial drug discov-
ery. Trends Parasitol. 2016;32:697–707.
 25. Chirawurah JD, Ansah F, Nyarko PB, Duodu S, Aniweh Y, Awandare GA. 
Antimalarial activity of Malaria Box compounds against Plasmodium falci-
parum clinical isolates. Int J Parasitol Drugs Drug Resist. 2017;7:399–406.
 26. Raphemot R, Lafuente-Monasterio MJ, Gamo-Benito FJ, Clardy J, Der-
byshire ER. Discovery of dual-stage malaria inhibitors with new targets. 
Antimicrob Agents Chemother. 2015;60:1430–7.
 27. Derbyshire ER, Min J, Guiguemde WA, Clark JA, Connelly MC, Magal-
haes AD, et al. Dihydroquinazolinone inhibitors of proliferation of 
blood and liver stage malaria parasites. Antimicrob Agents Chemother. 
2014;58:1516–22.
 28. Douglas RG, Amino R, Sinnis P, Frischknecht F. Active migration and pas-
sive transport of malaria parasites. Trends Parasitol. 2015;31:357–62.
 29. Sidjanski S, Vanderberg JP. Delayed migration of Plasmodium sporo-
zoites from the mosquito bite site to the blood. Am J Trop Med Hyg. 
1997;57:426–9.
 30. Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, Menard 
R. Quantitative imaging of Plasmodium transmission from mosquito to 
mammal. Nat Med. 2006;12:220–4.
 31. Hellmann JK, Munter S, Wink M, Frischknecht F. Synergistic and additive 
effects of epigallocatechin gallate and digitonin on Plasmodium sporozo-
ite survival and motility. PLoS ONE. 2010;5:e8682.
 32. Derbyshire ER, Mazitschek R, Clardy J. Characterization of Plasmodium 
liver stage inhibition by halofuginone. ChemMedChem. 2012;7:844–9.
 33. Klug D, Frischknecht F. Motility precedes egress of malaria parasites from 
oocysts. Elife. 2017;6:e19157.
 34. Sultan AA, Thathy V, Frevert U, Robson KJ, Crisanti A, Nussenzweig V, 
et al. TRAP is necessary for gliding motility and infectivity of Plasmodium 
sporozoites. Cell. 1997;90:511–22.
 35. Kariu T, Yuda M, Yano K, Chinzei Y. MAEBL is essential for malarial sporozo-
ite infection of the mosquito salivary gland. J Exp Med. 2002;195:1317–23.
 36. Ejigiri I, Ragheb DR, Pino P, Coppi A, Bennett BL, Soldati-Favre D, et al. 
Shedding of TRAP by a rhomboid protease from the malaria sporozoite 
Page 9 of 10Douglas et al. Malar J  (2018) 17:319 
surface is essential for gliding motility and sporozoite infectivity. PLoS 
Pathog. 2012;8:e1002725.
 37. Matsuoka H, Yoshida S, Hirai M, Ishii A. A rodent malaria, Plasmodium 
berghei, is experimentally transmitted to mice by merely probing of 
infective mosquito, Anopheles stephensi. Parasitol Int. 2002;51:17–23.
 38. Medica DL, Sinnis P. Quantitative dynamics of Plasmodium yoelii sporo-
zoite transmission by infected anopheline mosquitoes. Infect Immun. 
2005;73:4363–9.
 39. Frischknecht F, Baldacci P, Martin B, Zimmer C, Thiberge S, Olivo-Marin 
JC, et al. Imaging movement of malaria parasites during transmission 
by Anopheles mosquitoes. Cell Microbiol. 2004;6:687–94.
 40. Yamauchi LM, Coppi A, Snounou G, Sinnis P. Plasmodium sporozoites 
trickle out of the injection site. Cell Microbiol. 2007;9:1215–22.
 41. Heintzelman MB. Gliding motility in apicomplexan parasites. Semin 
Cell Dev Biol. 2015;46:135–42.
 42. Vanderberg JP, Frevert U. Intravital microscopy demonstrating 
antibody-mediated immobilisation of Plasmodium berghei sporozoites 
injected into skin by mosquitoes. Int J Parasitol. 2004;34:991–6.
 43. Frevert U, Engelmann S, Zougbede S, Stange J, Ng B, Matuschewski K, 
Liebes L, Yee H. Intravital observation of Plasmodium berghei sporozoite 
infection of the liver. PLoS Biol. 2005;3:e192.
 44. Tavares J, Formaglio P, Thiberge S, Mordelet E, Van Rooijen N, Medvin-
sky A, et al. Role of host cell traversal by the malaria sporozoite during 
liver infection. J Exp Med. 2013;210:905–15.
 45. Hopp CS, Chiou K, Ragheb DR, Salman A, Khan SM, Liu AJ, Sinnis P. 
Longitudinal analysis of Plasmodium sporozoite motility in the dermis 
reveals component of blood vessel recognition. Elife. 2015;4:e07789.
 46. Sinnis P, Zavala F. The skin: where malaria infection and the host 
immune response begin. Semin Immunopathol. 2012;34:787–92.
 47. Sinnis P, Zavala F. The skin stage of malaria infection: biology and 
relevance to the malaria vaccine effort. Future Microbiol. 2008;3:275–8.
 48. Vanderberg JP. Studies on the motility of Plasmodium sporozoites. J 
Protozool. 1974;21:527–37.
 49. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. Plasmodium berghei 
sporozoite invasion is blocked in vitro by sporozoite-immobilizing 
antibodies. Infect Immun. 1986;51:859–64.
 50. Hegge S, Kudryashev M, Smith A, Frischknecht F. Automated clas-
sification of Plasmodium sporozoite movement patterns reveals a shift 
towards productive motility during salivary gland infection. Biotechnol 
J. 2009;4:903–13.
 51. Hellmann JK, Munter S, Kudryashev M, Schulz S, Heiss K, Muller AK, 
et al. Environmental constraints guide migration of malaria parasites 
during transmission. PLoS Pathog. 2011;7:e1002080.
 52. Munter S, Sabass B, Selhuber-Unkel C, Kudryashev M, Hegge S, Engel U, 
et al. Plasmodium sporozoite motility is modulated by the turnover of 
discrete adhesion sites. Cell Host Microbe. 2009;6:551–62.
 53. Hegge S, Munter S, Steinbuchel M, Heiss K, Engel U, Matuschewski 
K, et al. Multistep adhesion of Plasmodium sporozoites. FASEB J. 
2010;24:2222–34.
 54. Wigger-Alberti W, Stauss-Grabo M, Grigo K, Atiye S, Williams R, Kort-
ing HC. Efficacy of a tyrothricin-containing wound gel in an abra-
sive wound model for superficial wounds. Skin Pharmacol Physiol. 
2013;26:52–6.
 55. Lang C, Staiger C. Tyrothricin—An underrated agent for the treat-
ment of bacterial skin infections and superficial wounds? Pharmazie. 
2016;71:299–305.
 56. Campo JJ, Sacarlal J, Aponte JJ, Aide P, Nhabomba AJ, Dobano C, 
et al. Duration of vaccine efficacy against malaria: 5th year of follow-
up in children vaccinated with RTS,S/AS02 in Mozambique. Vaccine. 
2014;32:2209–16.
 57. White MT, Bejon P, Olotu A, Griffin JT, Bojang K, Lusingu J, et al. A com-
bined analysis of immunogenicity, antibody kinetics and vaccine efficacy 
from phase 2 trials of the RTS,S malaria vaccine. BMC Med. 2014;12:117.
 58. Boucher LE, Hopp CS, Muthinja JM, Frischknecht F, Bosch J. Discovery 
of Plasmodium (M)TRAP-aldolase interaction stabilizers interfering with 
sporozoite motility and invasion. ACS Infect Dis. 2018;4:620–34.
 59. Zhang M, Fennell C, Ranford-Cartwright L, Sakthivel R, Gueirard P, Meister 
S, et al. The Plasmodium eukaryotic initiation factor-2alpha kinase IK2 
controls the latency of sporozoites in the mosquito salivary glands. J Exp 
Med. 2010;207:1465–74.
 60. Gomes-Santos CS, Braks J, Prudencio M, Carret C, Gomes AR, Pain A, et al. 
Transition of Plasmodium sporozoites into liver stage-like forms is regu-
lated by the RNA binding protein Pumilio. PLoS Pathog. 2011;7:e1002046.
 61. Moon RW, Taylor CJ, Bex C, Schepers R, Goulding D, Janse CJ, et al. A 
cyclic GMP signalling module that regulates gliding motility in a malaria 
parasite. PLoS Pathog. 2009;5:e1000599.
 62. Brochet M, Collins MO, Smith TK, Thompson E, Sebastian S, Volkmann K, 
et al. Phosphoinositide metabolism links cGMP-dependent protein kinase 
G to essential Ca(2)(+) signals at key decision points in the life cycle of 
malaria parasites. PLoS Biol. 2014;12:e1001806.
 63. Alam MM, Solyakov L, Bottrill AR, Flueck C, Siddiqui FA, Singh S, et al. 
Phosphoproteomics reveals malaria parasite Protein Kinase G as a signal-
ling hub regulating egress and invasion. Nat Commun. 2015;6:7285.
 64. Falae A, Combe A, Amaladoss A, Carvalho T, Menard R, Bhanot P. Role of 
Plasmodium berghei cGMP-dependent protein kinase in late liver stage 
development. J Biol Chem. 2010;285:3282–8.
 65. Morahan BJ, Wang L, Coppel RL. No TRAP, no invasion. Trends Parasitol. 
2009;25:77–84.
 66. Malpede BM, Tolia NH. Malaria adhesins: structure and function. Cell 
Microbiol. 2014;16:621–31.
 67. Shen B, Sibley LD. Toxoplasma aldolase is required for metabo-
lism but dispensable for host-cell invasion. Proc Natl Acad Sci USA. 
2014;111:3567–72.
 68. Jacot D, Tosetti N, Pires I, Stock J, Graindorge A, Hung YF, et al. An apicom-
plexan actin-binding protein serves as a connector and lipid sensor to 
coordinate motility and invasion. Cell Host Microbe. 2016;20:731–43.
 69. Stauss-Grabo M, Atiye S, Le T, Kretschmar M. Decade-long use of the 
antimicrobial peptide combination tyrothricin does not pose a major 
risk of acquired resistance with gram-positive bacteria and Candida spp. 
Pharmazie. 2014;69:838–41.
 70. Leitao R, Rodriguez A. Inhibition of Plasmodium sporozoites infection by 
targeting the host cell. Exp Parasitol. 2010;126:273–7.
 71. Gumila C, Ancelin ML, Delort AM, Jeminet G, Vial HJ. Characterization of 
the potent in vitro and in vivo antimalarial activities of ionophore com-
pounds. Antimicrob Agents Chemother. 1997;41:523–9.
 72. D’Alessandro S, Corbett Y, Ilboudo DP, Misiano P, Dahiya N, Abay SM, et al. 
Salinomycin and other ionophores as a new class of antimalarial drugs 
with transmission-blocking activity. Antimicrob Agents Chemother. 
2015;59:5135–44.
 73. Bane KS, Lepper S, Kehrer J, Sattler JM, Singer M, Reinig M, et al. The 
actin filament-binding protein coronin regulates motility in Plasmodium 
sporozoites. PLoS Pathog. 2016;12:e1005710.
 74. Douglas RG, Nandekar P, Aktories JE, Kumar H, Weber R, Sattler JM, et al. 
Inter-subunit interactions drive divergent dynamics in mammalian and 
Plasmodium actin filaments. PLoS Biol. 2018;16:e2005345.
 75. Muthinja JM, Ripp J, Kruger T, Imle A, Haraszti T, Fackler OT, et al. Tailored 
environments to study motile cells and pathogens. Cell Microbiol. 
2018;20:e12820.
 76. Yang X, Yousef AE. Antimicrobial peptides produced by Brevibacillus spp.: 
structure, classification and bioactivity: a mini review. World J Microbiol 
Biotechnol. 2018;34:57.
 77. Otten-Kuipers MA, Coppens-Burkunk GW, Kronenburg NA, de Vis MA, 
Roelofsen B, Op den Kamp JA. Tryptophan-N-formylated gramicidin 
causes growth inhibition of Plasmodium falciparum by inducing potas-
sium efflux from infected erythrocytes. Parasitol Res. 1997;83:185–92.
 78. Otten-Kuipers MA, Franssen FF, Nieuwenhuijs H, Overdulve JP, Roelofsen 
B, Op den Kamp JA. Effect of tryptophan-N-formylated gramicidin on 
growth of Plasmodium berghei in mice. Antimicrob Agents Chemother. 
1997;41:1778–82.
 79. Rautenbach M, Vlok NM, Stander M, Hoppe HC. Inhibition of malaria 
parasite blood stages by tyrocidines, membrane-active cyclic peptide 
antibiotics from Bacillus brevis. Biochim Biophys Acta. 2007;1768:1488–97.
 80. Urry DW, Goodall MC, Glickson JD, Mayers DF. The gramicidin A trans-
membrane channel: characteristics of head-to-head dimerized (L, D) 
helices. Proc Natl Acad Sci USA. 1971;68:1907–11.
 81. Seoh SA, Busath D. The permeation properties of small organic cations in 
gramicidin A channels. Biophys J. 1993;64:1017–28.
 82. Kiricsi M, Prenner EJ, Jelokhani-Niaraki M, Lewis RN, Hodges RS, McEl-
haney RN. The effects of ring-size analogs of the antimicrobial peptide 
gramicidin S on phospholipid bilayer model membranes and on the 
growth of Acholeplasma laidlawii B. Eur J Biochem. 2002;269:5911–20.
Page 10 of 10Douglas et al. Malar J  (2018) 17:319 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 83. Stein BS, Bensch KG, Sussman HH. Complete inhibition of transferrin 
recycling by monensin in K562 cells. J Biol Chem. 1984;259:14762–72.
 84. Matheke ML, Fliesler SJ, Basinger SF, Holtzman E. The effects of monensin 
on transport of membrane components in the frog retinal photorecep-
tor. I. Light microscopic autoradiography and biochemical analysis. J 
Neurosci. 1984;4:1086–92.
 85. Banerjee S, Argaez C. In: Topical antibiotics for infection prevention: a 
review of the clinical effectiveness and guidelines. Ottawa (ON); 2017.
 86. Kuchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, Schafer-
Korting M, Kramer KD. Nanoparticles for skin penetration enhance-
ment—a comparison of a dendritic core-multishell-nanotransporter and 
solid lipid nanoparticles. Eur J Pharm Biopharm. 2009;71:243–50.
 87. Contri RV, Fiel LA, Alnasif N, Pohlmann AR, Guterres SS, Schafer-Korting 
M. Skin penetration and dermal tolerability of acrylic nanocapsules: 
influence of the surface charge and a chitosan gel used as vehicle. Int J 
Pharm. 2016;507:12–20.
 88. Schulz R, Yamamoto K, Klossek A, Flesch R, Honzke S, Rancan F, et al. Data-
based modeling of drug penetration relates human skin barrier function 
to the interplay of diffusivity and free-energy profiles. Proc Natl Acad Sci 
USA. 2017;114:3631–6.
 89. Marren K. Dimethyl sulfoxide: an effective penetration enhancer for topi-
cal administration of NSAIDs. Phys Sportsmed. 2011;39:75–82.
